A Phase 3 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 33 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 73rd largest by enrollment, is one of 14 that started in 2016, is one of 56 in phase 3, and was the 168th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 14 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 55th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2016, is one of 35 in phase 3, and was the 103rd registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis.
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF/VEL for 12 weeks
Drug: SOF/VEL
SOF/VEL + RBV for 12 weeks
Drug: SOF/VEL · Drug: RBV
Drug pages: Sofosbuvir · Velpatasvir
400/100 mg FDC tablet administered orally once daily
Also known as: Epclusa®
Capsules administered orally in a divided daily dose
Also known as: Rebetol®
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Discontinued Treatment (SOF/VEL or RBV) Early Due to an Adverse Event
Time frame: Up to 12 weeks
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
Time frame: Posttreatment Week 24
Percentage of Participants Who Had HCV RNA < LLOQ by Visit While on Treatment
Time frame: Up to 12 weeks
Change From Baseline in HCV RNA
Time frame: Baseline and up to 12 weeks
Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.
Time frame: Baseline to Posttreatment Week 24
Percentage of Participants With Improved and Worsened Child-Pugh-Turcotte (CPT) Class
CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. CPT scores were calculated using prothrombin activation percentage for the coagulation parameter per Japan's standard.
Time frame: Baseline to Posttreatment Week 24
Percentage of Participants With Virologic Failure
Virologic failure was defined as: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement).
Time frame: Up to Posttreatment Week 24
Participants were enrolled at study sites in Japan. The first participant was screened on 26 December 2016. The last study visit occurred on 08 May 2018.
| Milestone | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Started | 51 | 51 |
| Completed | 51 | 48 |
| Not completed | 0 | 3 |
| Withdrew: Death | 0 | 3 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 92.2 (81.1 to 97.8) | 92.2 (81.1 to 97.8) |
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Discontinuation of SOF/VEL | 0 | 3.9 |
| Discontinuation of RBV | NA | 17.6 |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) | 94.1 (83.8 to 98.8) | 96.1 (86.5 to 99.5) |
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) | 92.2 (81.1 to 97.8) | 92.2 (81.1 to 97.8) |
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Week 2 | 45.1 | 51.0 |
| Week 4 | 96.1 | 90.2 |
| Week 8 | 100.0 | 96.1 |
| Week 12 | 100.0 | 100.0 |
| log10 IU/mL | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Change at Week 2 | -4.14 ± 0.573 | -4.33 ± 0.525 |
| Change at Week 4 | -4.55 ± 0.696 | -4.65 ± 0.528 |
| Change at Week 8 | -4.56 ± 0.705 | -4.70 ± 0.554 |
| Change at Week 12 | -4.56 ± 0.705 | -4.70 ± 0.554 |
MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Decrease (Improvement) | 38.3 | 21.7 |
| No Change | 53.2 | 54.3 |
| Increase (Worsening) | 8.5 | 23.9 |
CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. CPT scores were calculated using prothrombin activation percentage for the coagulation parameter per Japan's standard.
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Improved CPT Class | 36.2 | 39.1 |
| Worsened CPT Class | 4.3 | 2.2 |
Virologic failure was defined as: Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement).
| Percentage of participants | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Percentage of Participants With Virologic Failure | 7.8 | 3.9 |
Collected over Adverse Events: Up to 12 weeks plus 30 days; All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF/VEL | 0/51 (0%) | 4/51 (7.8%) | 14/51 (27.5%) |
| SOF/VEL + RBV | 3/51 (5.9%) | 7/51 (13.7%) | 34/51 (66.7%) |
| Event | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/51 | 2/51 |
| Hepatic encephalopathyNervous system disorders | 1/51 | 2/51 |
| AnaemiaBlood and lymphatic system disorders | 0/51 | 1/51 |
| AscitesGastrointestinal disorders | 0/51 | 1/51 |
| Gastric varices haemorrhageGastrointestinal disorders | 0/51 | 1/51 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 0/51 | 1/51 |
| Varices oesophagealGastrointestinal disorders | 1/51 | 0/51 |
| Bacterial sepsisInfections and infestations | 0/51 | 1/51 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/51 |
| Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/51 |
| Event | SOF/VEL | SOF/VEL + RBV |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/51 | 19/51 |
| DiarrhoeaGastrointestinal disorders | 0/51 | 7/51 |
| NasopharyngitisInfections and infestations | 7/51 | 3/51 |
| Back painMusculoskeletal and connective tissue disorders | 0/51 | 4/51 |
| HeadacheNervous system disorders | 1/51 | 4/51 |
| InsomniaPsychiatric disorders | 0/51 | 4/51 |
| RashSkin and subcutaneous tissue disorders | 4/51 | 1/51 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/51 | 3/51 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/51 | 3/51 |
| Oedema peripheralGeneral disorders | 3/51 | 2/51 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Mean | 66 ± 9.6 | 66 ± 9.6 | 66 ± 9.5 |
| Sex: Female, Male(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Female | 33 | 29 | 62 |
| Male | 18 | 22 | 40 |
| Ethnicity (NIH/OMB)(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 51 | 51 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 51 | 51 | 102 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| HCV genotype(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Genotype 1 | 41 | 39 | 80 |
| Genotype 2 | 9 | 11 | 20 |
| Genotype 3 | 1 | 0 | 1 |
| Missing | 0 | 1 | 1 |
| IL28b Status(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| CC | 33 | 37 | 70 |
| CT | 16 | 13 | 29 |
| TT | 2 | 1 | 3 |
| HCV RNA (log10 international units per milliliter [IU/mL])(log10 IU/mL) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| Mean | 5.7 ± 0.70 | 5.8 ± 0.55 | 5.8 ± 0.63 |
| HCV RNA Category(Participants) | SOF/VEL | SOF/VEL + RBV | Total |
|---|---|---|---|
| < 800,000 IU/mL | 30 | 30 | 60 |
| ≥ 800,000 IU/mL | 21 | 21 | 42 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2016 to primary completion in Feb 2018, 13 months.
Results were first posted in Feb 2019, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 13 months is close to that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin